Vas Narasimhan
SwitzerlandCEOMale6.0Global Dominance: 0.00%Vas Narasimhan is the Chief Executive Officer of Novartis, a leading global healthcare company. Under his leadership, he has focused on advancing innovative therapies while addressing challenges in healthcare costs and access. Narasimhan advocates for sustainable practices in the pharmaceutical industry, emphasizing the need for ethical pricing of medications to ensure that life-saving treatments are accessible to all patients.
Country presence
Recent news mentions
Vas Narasimhan is the CEO of Novartis, who participated in the announcement of drug pricing agreements.
Die USA untersuchen die Medikamentenpreise in DeutschlandSwitzerland· 2026-06-20
Vas Narasimhan is the CEO of Novartis who participated in discussions about drug pricing agreements with the US government.
Neues Werk von BMS in Boudry erhält Konkurrenz aus USASwitzerland· 2026-05-28
Vas Narasimhan is the CEO of Novartis and participated in the announcement of the drug pricing deal with the US government.
«Es steht viel auf dem Spiel»Switzerland· 2026-03-07
Vas Narasimhan is the CEO of Novartis and is married to Srishti Gupta.
Die Biotechfirma Idorsia baut auch unter Srishti Gupta Stellen abSwitzerland· 2026-02-27
Novartis-CEO Vas Narasimhan received 25 million francs last year.
Von den hohen Gehältern der Multis profitieren alleSwitzerland· 2026-02-14
Vas Narasimhan, CEO of Novartis, attended the announcement of a deal with the U.S. government to lower drug prices.
Was bringt Donald Trumps Medikamenten-Website?Switzerland· 2026-02-07
Vas Narasimhan, the CEO of Novartis, earned nearly 25 million francs in 2025, sparking public outrage over his salary.
Lohn von Novartis-CEO Vas Narasimhan: Provokation aber NebenschauplatzSwitzerland· 2026-02-04Vas Narasimhan has been leading the Swiss pharmaceutical company Novartis for eight years and is focused on further expansion.
Lohn des Novartis-Chefs steigt auf fast 25 Millionen FrankenSwitzerland· 2026-02-04
Vas Narasimhan is the CEO of Novartis and was involved in discussions regarding drug pricing with the U.S. government.
Roche macht deutlich mehr GewinnSwitzerland· 2026-01-29
Vas Narasimhan, CEO of Novartis, received high marks for his functional reputation among Swiss CEOs.
CEO auf dem Schleudersitz: KI-Tool berechnet ReputationsrisikenSwitzerland· 2026-01-25
Vas Narasimhan, CEO of Novartis, attended the announcement at the White House.
Chinesische Firmen holen in Entwicklung aufSwitzerland· 2026-01-14Vas Narasimhan, the CEO of Novartis, is involved in discussions about drug pricing strategies.
«Standortwettbewerb hat neue Dimension erreicht»Switzerland· 2025-12-24
Vas Narasimhan is the CEO of Novartis who has also expressed concerns regarding the agreement with the US.
Willkommener Weckruf für die SchweizSwitzerland· 2025-12-22Vas Narasimhan, the CEO of Novartis, tempered high expectations from the White House regarding job creation.
Investitionszusagen steigen auf fast 400 MilliardenSwitzerland· 2025-12-05
Vas Narasimhan is the CEO of Novartis and assured that the negotiations with the American government are going well.
Novartis schliesst zu Roche und AstraZeneca aufSwitzerland· 2025-11-20Vas Narasimhan, the CEO of Novartis, has stated that the medication prices in Switzerland are much too low.
Trump verhilft Big Pharma zu höheren Preisen in EuropaSwitzerland· 2025-11-13
Vas Narasimhan is the CEO of Novartis and is leading the company's acquisition of Avidity Biosciences.
Novartis z nakupom Avidityja Biosciences stavi na terapije RNA
Slovenia· 2025-11-02Vas Narasimhan is the CEO of Novartis and commented on discussions with the US government regarding price reductions.
Novartis: Aktie taucht nach QuartalszahlenSwitzerland· 2025-10-28Vas Narasimhan stated that they are trying to avoid situations where they have to completely withdraw a product from the market.
Trump empuja a las farmacéuticas a subir los precios de los medicamentos en Europa para bajarlos en EE UU | Sociedad
Spain· 2025-10-06
Vas Narasimhan, CEO of Novartis, mentioned that prices in Switzerland are 'much too low'.
Trump will gegen mächtige Mittelsmänner im US-Gesundheitssystem vorgehenSwitzerland· 2025-10-06
Vas Narasimhan, CEO of Novartis, stated that they aim to minimize the price difference between the US and other industrialized countries.
Trump und Pfizer mit Abkommen: Günstigere Medikamente im DirektverkaufSwitzerland· 2025-10-01
Vas Narasimhan, CEO of Novartis, stated that drug prices in Switzerland are 'much too low'.
Wie geheime Rabatte Trumps Forderungen unterstützenSwitzerland· 2025-09-28Vas Narasimhan is the CEO of Novartis and has expressed ambivalence about his acceptance in Switzerland.
Ein Opfer der rassistischen Schweiz?Switzerland· 2025-09-20
Vas Narasimhan is the CEO of Novartis, who has been recognized for transparency in compensation.
Holcim-CEO war bestbezahlter CEO 2024Switzerland· 2025-08-21
Vas Narasimhan, the CEO of Novartis, commented on the need for Europeans to pay more for medications.
«Zölle motivieren nicht zu Investitionen in den USA»Switzerland· 2025-08-08
Vas Narasimhan is the CEO of Novartis, involved in discussions regarding pharmaceutical pricing with the US government.
Auf diese Politiker kommt es jetzt anSwitzerland· 2025-08-05
Novartis CEO Vas Narasimhan received one of Trump's letters and criticized the Europeans for not paying enough for innovative drugs.
Donald Trump fordert tiefere Medikamentenpreise innert 60 TagenSwitzerland· 2025-07-31
Vas Narasimhan, the CEO of Novartis, reaffirmed his claim that drug prices in Europe need to rise significantly.
Aus Sorge um Zölle lässt Roche den Ausblick lieber unverändertSwitzerland· 2025-07-24
Vas Narasimhan is the CEO of the pharmaceutical company Novartis and advocates for higher medication prices in Europe.
Novartis-Chef fordert höhere Medikamentenpreise in EuropaSwitzerland· 2025-07-17
Novartis CEO Vas Narasimhan remarked, 'For more than three decades, we have stayed the course in the fight against malaria.'
Kenya takes part in trials of first malaria treatment for newborns
Kenya· 2025-07-15
